Chih‐Hung Chiang
Papers
1
Total Citations
9
H-Index
1
About
Dr. Chih-Hung Chiang is a leading urological researcher whose work centers on improving prostate cancer (PCa) diagnostics and prognostication. His primary contributions lie in refining the use of novel biomarkers to predict aggressive disease, particularly through the Prostate Health Index (PHI) and its derivative, %p2PSA. In a landmark 2020 study, which has garnered 9 citations, Dr. Chiang demonstrated that preoperative %p2PSA and PHI scores can accurately predict adverse pathological outcomes—such as extraprostatic extension and seminal vesicle invasion—in patients undergoing radical prostatectomy. This work is pivotal for clinical decision-making, helping to identify which men with organ-confined PCa truly require aggressive surgical intervention versus active surveillance. By validating these biomarkers in a cohort of 91 robot-assisted RP patients, Dr. Chiang has provided urologists with a non-invasive tool to stratify risk more precisely, potentially reducing overtreatment. His research bridges the gap between laboratory science and bedside practice, offering a tangible pathway toward personalized prostate cancer management. For students and clinicians alike, Dr. Chiang’s work exemplifies how targeted biomarker studies can directly enhance surgical planning and patient outcomes.
Research Focus
Key Achievements
Top Papers
- 1